FDA Strengthens Safety Label Warnings for Fluoroquinolone Antibiotics
The Food and Drug Administration yesterday announced safety labeling changes for fluoroquinolone antibiotics to strengthen warnings about the risk of mental health side effects and serious blood sugar disturbances. Based on a recent FDA review of adverse event reports and the medical literature, the updated labeling will highlight mental health side effects including disturbances in attention, disorientation, agitation, nervousness, memory impairment and delirium, and the potential risk of coma with hypoglycemia. Fluoroquinolone antibiotics are used to treat certain serious bacterial infections.
Related News Articles
Headline
Elizabeth Mort, M.D., vice president and chief medical officer at Joint Commission, breaks down the five critical priorities boards must focus on — …
Blog
High-quality maternal care is essential to protecting the health of both mom and baby during birth.Sutter Health is taking a proactive, systemwide approach to…
Headline
USA Today published a column by AHA Board Chair Marc Boom, M.D., president and CEO of Houston Methodist, highlighting how hospitals and health systems…
Blog
h2, h3, h4 {color: #002855;}
Postpartum hemorrhage (PPH) is one of the most common — and preventable — causes of maternal health in the United States. The…
Chairperson's File
For decades, hospitals and health systems have used innovation to improve patient care and outcomes. We have seen dramatic improvements and know we can never…
Headline
March 8-14 marks Patient Safety Awareness Week. The AHA has several resources including podcasts, videos and reports that show how AHA members are advancing…